WO 2004/003163 PCT/US2003/020508

## Claims

- 1. An isolated polynucleotide comprising SEQ ID 1.
- 2. An isolated polynucleotide comprising SEQ ID 2.
- 3. An isolated polypeptide comprising SEQ ID 3.
- 4. An isolated polypeptide comprising SEQ ID 4.
- 5. An isolated polypeptide comprising SEQ ID 5.
- 6. An isolated polypeptide comprising SEQ ID 6.
- 7. A method of directing the navigation of physiological tracking tubular structures that express Robo-4 receptor away from a target cell mass, comprising expressing a ligand of said Robo-4 receptor in said target cell mass and allowing binding between the ligand and said Robo-4 receptor.
  - 8. The method of claim 7, wherein the ligand comprises Slit ligand.
- 9. The method of claim 7, wherein said physiological tracking tubular structures comprise endothelial tubes.
- 10. A method of directing the navigation of physiological tracking tubular structures that express Robo-4 receptor toward a target cell mass, comprising expressing a ligand of said Robo-4 receptor in a second cell mass and allowing binding between the ligand and said Robo-4 receptor.

WO 2004/003163 PCT/US2003/020508

- 11. The method of claim 10, wherein the ligand comprises Slit ligand
- 12. The method of claim 10, wherein said physiological tracking tubular structures comprise endothelial tubes.
- 13. A method of disrupting navigation of physiological tracking tubular structures that express Robo-4 receptor, comprising inhibiting activation of said Robo-4 receptor.
- 14. The method of claim 13, wherein said physiological tracking tubular structures comprise endothelial tubes.
- 15. A method of inducing angiogenesis in endothelium tissue expressing Robo-4 receptor, comprising inhibiting activation of said Robo-4 receptor.
- 16. The method of claim 15, wherein inhibiting activation of said Robo-4 receptor comprises providing a soluble form of said Robo-4 receptor to said endothelium tissue.
- 17. The method of claim 16, wherein the soluble form of said Robo-4 receptor comprises SEQ ID 6.

WO 2004/003163 PCT/US2003/020508

18. The method of claim 16, wherein the soluble form of said Robo-4 receptor comprises an amino acid sequence having at least 80% sequence identity to SEQ ID 6, or a fragment thereof.

- 19. A method of preventing angiogenesis in endothelium tissue expressing Robo-4 receptor, comprising activating said Robo-4 receptor.
- 20. The method of claim 19, wherein activating said Robo-4 receptor comprises providing a ligand of said Robo-4 receptor and allowing the ligand to bind to said Robo-4 receptor.
  - 21. The method of claim 20, wherein the ligand comprises Slit ligand.
- 22. The method according to any of claim 7, 10 and 20, wherein the ligand comprises human Slit2 ligand, or a fragment thereof.